Cargando…

Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial

BACKGROUND: Pneumonia is still the leading cause of death among children in Africa, and pneumococcal serotypes 1 and 5 are frequently isolated from African children with invasive pneumococcal disease below the age of 5 years. The immunogenicity, safety and reactogenicity of 3-dose primary vaccinatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dicko, Alassane, Odusanya, Olumuyiwa O, Diallo, Abdoulbaki I, Santara, Gaoussou, Barry, Amadou, Dolo, Amagana, Diallo, Aminata, Kuyinu, Yetunde A, Kehinde, Omolara A, François, Nancy, Borys, Dorota, Yarzabal, Juan P, Moreira, Marta, Schuerman, Lode
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267728/ https://www.ncbi.nlm.nih.gov/pubmed/22112189 http://dx.doi.org/10.1186/1471-2458-11-882

Ejemplares similares

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children
por: Dicko, Alassane, et al.
Publicado: (2013)

Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study
por: Dicko, Alassane, et al.
Publicado: (2015)

Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life
por: Odusanya, Olumuyiwa O, et al.
Publicado: (2014)

Effects of Vaccination with 10-Valent Pneumococcal Non-Typeable Haemophilus influenza Protein D Conjugate Vaccine (PHiD-CV) on the Nasopharyngeal Microbiome of Kenyan Toddlers
por: Feazel, Leah M., et al.
Publicado: (2015)

Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries
por: Marijam, Alen, et al.
Publicado: (2022)

Malaria Morbidity in Children in the Year after They Had Received Intermittent Preventive Treatment of Malaria in Mali: A Randomized Control Trial
por: Dicko, Alassane, et al.
Publicado: (2011)

Intermittent Preventive Treatment of Malaria Provides Substantial Protection against Malaria in Children Already Protected by an Insecticide-Treated Bednet in Mali: A Randomised, Double-Blind, Placebo-Controlled Trial
por: Dicko, Alassane, et al.
Publicado: (2011)

A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
por: Lee, Soon Min, et al.
Publicado: (2018)

Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial
por: Tregnaghi, Miguel W., et al.
Publicado: (2014)

10‐valent pneumococcal non‐typeable Haemophilus influenzae protein‐D conjugate vaccine (PHiD‐CV) induces memory B cell responses in healthy Kenyan toddlers
por: Muema, D. M., et al.
Publicado: (2015)

Correction: Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial
por: Tregnaghi, Miguel W., et al.
Publicado: (2015)

A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia
por: Lim, Fong Seng, et al.
Publicado: (2014)

Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland
por: Vesikari, Timo, et al.
Publicado: (2016)

Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – A randomized controlled trial
por: Sáez-Llorens, Xavier, et al.
Publicado: (2017)

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea
por: Zhang, Xu-Hao, et al.
Publicado: (2017)

A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand
por: Varghese, Lijoy, et al.
Publicado: (2018)

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial
por: Falup-Pecurariu, Oana, et al.
Publicado: (2016)

Health literacy: Prevalence and determinants in Lagos State, Nigeria
por: Kuyinu, Yetunde Abiola, et al.
Publicado: (2020)

Adverse pregnancy outcomes among women presenting at antenatal clinics in Ouélessébougou, Mali
por: Andemel, Naissem, et al.
Publicado: (2020)

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
por: Castiglia, Paolo, et al.
Publicado: (2017)

Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model
por: Delgleize, Emmanuelle, et al.
Publicado: (2016)

Artificial Intelligence approaches to predict COVID-19 infection in Senegal
por: Diallo, Abdoulaye, et al.
Publicado: (2022)

Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali
por: Dicko, Alassane, et al.
Publicado: (2008)

A malariometric survey of under-fives residing in indoor residual spraying-implementing and non-implementing communities of Lagos, Nigeria
por: Odugbemi, Babatunde A., et al.
Publicado: (2016)

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia
por: Wang, Xiao Jun, et al.
Publicado: (2017)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

Phase 1 Study of a Combination AMA1 Blood Stage Malaria Vaccine in Malian Children
por: Dicko, Alassane, et al.
Publicado: (2008)

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status
por: Madhi, Shabir A., et al.
Publicado: (2017)

Le vaccin antipaludique RTS,S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination
por: Vandoolaeghe, Pascale, et al.
Publicado: (2018)

10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial
por: Oguoma, Victor M, et al.
Publicado: (2020)

Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study
por: Iwata, Satoshi, et al.
Publicado: (2015)

Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine
por: Leach, Amanda Jane, et al.
Publicado: (2015)

Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians
por: Dicko, Alassane, et al.
Publicado: (2007)

Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali
por: Dicko, Alassane, et al.
Publicado: (2010)

Commentary in reply to a publication on Plasmodium falciparum pre-erythrocytic stage vaccine development
por: Roman, François P., et al.
Publicado: (2020)

Determinants of vaccination coverage in rural Nigeria
por: Odusanya, Olumuyiwa O, et al.
Publicado: (2008)

Pneumococcal vaccine impacts on the population genomics of non-typeable Haemophilus influenzae
por: Cleary, David, et al.
Publicado: (2018)

Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
por: Hausdorff, William P, et al.
Publicado: (2010)

Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan
por: Lu, Chun-Yi, et al.
Publicado: (2020)

Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial
por: Rinta-Kokko, Hanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jofbucaaerje0igo8b2ojnl65i